Pamiparib is under clinical development by BeiGene and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pamiparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pamiparib is an anti-neoplastic agent. It is formulated as capsules for oral route of administration. Pamiparib is indicated for the treatment of patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.
Pamiparib (BGB-290) is under development for the treatment of metastatic or unresectable renal cell carcinoma, advanced or metastatic adenocarcinoma of the stomach or gastro esophageal junction, relapsed or refractory solid tumors including recurrent glioblastoma multiforme (GBM), cervical cancer, bile duct cancer, peripheral nerve sheath cancer, ovarian cancer, endometrial cancer, triple negative breast cancer, metastatic HR positive and HER2 negative breast cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, leiomyosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, myxofibrosarcoma, primary peritoneal cancer, fallopian cancer, metastatic castration-resistant prostate cancer (mCRPC), high-grade glioma, low-grade glioma, colorectal cancer, metastatic adenocarcinoma of the pancreas, muscle invasive bladder cancer, transitional cell cancer(urothelial cell cancer), small-cell lung cancer and pancreatic cancer. The drug candidate is administered orally. It targets the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2).
BeiGene is a biotechnology company. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). BeiGene is investigating Zanubrutinib (BGB-3111), a small molecule inhibitor of BTK to treat B cell malignancies; Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. It seeks to work in partnership with academia, biotechnology and pharmaceutical companies to develop treatments for cancer patients. The company has operations in the US, Australia, Germany, Spain Switzerland, and Italy. BeiGene is headquartered in Beijing, China.
For a complete picture of Pamiparib’s drug-specific PTSR and LoA scores, buy the report here.